Neuropace/$NPCE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Neuropace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Ticker
$NPCE
Sector
Primary listing
Employees
209
Headquarters
Website
Neuropace Metrics
BasicAdvanced
$325M
-
-$0.84
1.90
-
Price and volume
Market cap
$325M
Beta
1.9
52-week high
$18.98
52-week low
$5.45
Average daily volume
197K
Financial strength
Current ratio
5.468
Quick ratio
4.416
Long term debt to equity
357.717
Total debt to equity
367.934
Interest coverage (TTM)
-2.31%
Profitability
EBITDA (TTM)
-19.659
Gross margin (TTM)
75.74%
Net profit margin (TTM)
-29.29%
Operating margin (TTM)
-22.43%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-12.39%
Return on equity (TTM)
-176.94%
Valuation
Price to revenue (TTM)
3.429
Price to book
16.69
Price to tangible book (TTM)
16.69
Price to free cash flow (TTM)
-18.483
Free cash flow yield (TTM)
-5.41%
Free cash flow per share (TTM)
-0.531
Growth
Revenue change (TTM)
23.32%
Earnings per share change (TTM)
-22.87%
3-year revenue growth (CAGR)
27.32%
3-year earnings per share growth (CAGR)
-21.95%
What the Analysts think about Neuropace
Analyst ratings (Buy, Hold, Sell) for Neuropace stock.
Bulls say / Bears say
NeuroPace reported record Q2 2025 revenue of $23.5 million, representing 22% year-over-year growth driven by increased RNS System sales (GlobeNewswire )(Investing.com)
The company’s gross margin improved to 77.1% in Q2 2025 from 73.4% in Q2 2024, reflecting manufacturing efficiencies and a favorable product mix (GlobeNewswire )(Investing.com)
Three-year Post-Approval Study data showed an 82% median reduction in seizures at three years, underscoring the long-term efficacy of the RNS System in drug-resistant focal epilepsy (GlobeNewswire )(Investing.com)
NeuroPace reported a net loss of $8.7 million in Q2 2025, widening from $7.5 million in the year-ago quarter, indicating continued unprofitability (GlobeNewswire )(Investing.com)
Cash, cash equivalents, and short-term investments declined to $62.1 million at June 30, 2025, down from $66.3 million at the end of Q1 2025, tightening the company’s financial runway (GlobeNewswire)
Preliminary one-year data from the NAUTILUS study for idiopathic generalized epilepsy did not meet its primary effectiveness endpoint, potentially delaying FDA expansion into the IGE indication (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2025.
Neuropace Financial Performance
Revenues and expenses
Neuropace Earnings Performance
Company profitability
Neuropace News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neuropace stock?
Neuropace (NPCE) has a market cap of $325M as of September 16, 2025.
What is the P/E ratio for Neuropace stock?
The price to earnings (P/E) ratio for Neuropace (NPCE) stock is 0 as of September 16, 2025.
Does Neuropace stock pay dividends?
No, Neuropace (NPCE) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Neuropace dividend payment date?
Neuropace (NPCE) stock does not pay dividends to its shareholders.
What is the beta indicator for Neuropace?
Neuropace (NPCE) has a beta rating of 1.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.